益生菌辅助治疗非酒精性脂肪性肝病的效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy of probiotics in adjuvant treatment of non-alcoholic fatty liver disease(NAFLD).Methods Seventy-two patients diagnosed with NAFLD in Fujian Provincial Hospital from January 2018 to December 2019 were selected as subjects.They were divided into observation group(n=36)and control group(n=36)by random number table method.The control group was treated with conventional symptomatic treatment,and the observation group was treated with conventional symptomatic treatment plus oral intestinal probiotics.Alanine aminotransferase(ALT),aspartate aminotransferase(AST),γ -glutamyl transpeptidase(GGT),total bilirubin(TBil),total cholesterol(TC),triacylglycerol(TG),tumor necrosis factor-α(TNF-α)and body mass index(BMI)were compared between the two groups before and after treatment.Results After treatment,ALT,AST,GGT,TBil,TC,TG,TNF-α and BMI in the two groups were lower than those before treatment,the differences were statistically significant(P<0.05).After treatment,ALT,AST,GGT,TC and TG in observation group were lower than those in control group,the differences were statistically significant(P<0.05).There were no significant differences in TBil,TNF-α and BMI between the two groups(P>0.05).Conclusion Taking proper amount of probiotics has a certain positive effect on adjuvant treatment of NAFLD.

Key words： Probiotics Adjuvant treatment Non-alcoholic fatty liver disease Clinical curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HU Xiao

Cite this article:

HU Xiao. Effect of probiotics in adjuvant treatment of non-alcoholic fatty liver disease[J]. 中国当代医药, 2021, 28(25): 167-170.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I25/167

[1]	刘晓贞，徐积兄.肠道菌群与非酒精性脂肪肝关系的研究进展[J].中国老年学杂志，2019，39（11）：2815-2818.
[2]	中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南（2018 更新版）[J].传染病信息，2018，31（5）：393-420.
[3]	Younossi ZM.Non-Alcoholic fatty liver disease-A global public health perspective[J].J Hepatol，2018，70（3）：531-544.
[4]	杨蕊旭，范建高.非酒精性脂肪性肝病的流行特征[J].传染病信息，2018，31（2）：101-104.
[5]	孙海丽，刘鹏飞.以肠道菌群为靶点的非酒精性脂肪肝防治方法应用进展[J].山东医药，2018，58（39）：111-114.
[6]	单蕊，陈燕，姚政，等.肠道菌群与非酒精性脂肪肝病相关性研究进展[J].中国微生态学杂志，2019，31（7）：841-843.
[9]	孙超，范建高.中外非酒精性脂肪性肝病诊疗指南解读[J].中国实用内科杂志，2019，39（3）：235-238.
[10]	卢双，沈天白，陈阳，等.调节肠道菌群治疗非酒精脂肪肝的研究进展[J].肝脏，2019，24（5）：585-587.
[11]	Saltzman ET，Talia P，Michael T，et al.Intestinal microbiome shifts，dysbiosis，inflammation，and non-alcoholic fatty liver disease[J].Front Microbiol，2018，9：61.
[7]	Cui Y，Wang Q，Chang R，et al.Intestinal barrier function-nonalcoholic fatty liver disease interactions and possible role of gut microbiota[J].J Agric Food Chem，2019，67（10）：2754-2762.
[8]	Jasirwan COM，Lesmana CRA，Hasan I，et al.The role of gut microbiota in non-alcoholic fatty liver disease：pathways of mechanisms[J].Biosci Microbiota Food Health，2019，38（3）：81-88.
[12]	梁源，于瑞丽，尹悦，等.肠道菌群及其代谢产物在糖脂代谢中的作用[J].生理科学进展，2019，50（5）：321-325.
[13]	杨彦强，陈文美.非酒精性脂肪肝与肠道益生菌相关性研究进展[J].世界临床医学，2017，11（14）：111-112.
[14]	Liu L，Li P，Liu Y，et al.Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease：A Meta-Analysis[J].Dig Dis Sci，2019，64（12）：3402-3412.
[15]	中国食品科学技术学会益生菌分会.益生菌的科学共识（2020年版）[J].中国食品学报，2020，20（5）：303-307.
[16]	刘巧红，赵瑜，胡义扬.调节肠道菌群治疗非酒精性脂肪肝的研究进展[J].世界中医药，2020，15（7）：1075-1079.
[17]	朱悦，季国忠，杨丽华.非酒精性脂肪性肝炎的无创诊断评估研究进展[J].肝脏，2020，25（10）：1128-1132.
[18]	Karlas T，Petroff D，Sasso M，et al.Individual patient data meta-analysis of controlled attenuation parameter（CAP）technology for assessing steatosis[J].J Hepatol，2016，66（5）：1022-1030.